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Manuscript 
Orthodontic researchers have developed a novel way to enhance comprehensive orthodontic 
treatment with fixed appliances using supplemental irradiation with infrared light. Their rationale is 
founded on basic biological principles and their own clinical experience with prototype appliances. 
In order to initiate commercial production of infrared irradiation as an adjunct to orthodontic 
treatment and market their own device under the name Infrabrace, they decided to test their 
experimental appliance with a clinical trial. 
The authors performed a controlled clinical trial to assess the treatment effects of 
Infrabrace in a parallel trial with two patient groups. Patients in the first group (henceforth, called 
the experimental group) were treated with fixed appliances in conjunction with a daily 30 minute 
use of the experimental Infrabrace appliance, while patients in the second group (henceforth, 
called the control group) were treated with conventional fixed appliances without Infrabrace. The 
authors recruited for this study 60 consecutive adolescent patients from the private practice of an 
orthodontist, who were divided in two groups of 30 patients each with similar age and sex (Table). 
Both groups were treated with the same protocol regarding fixed appliance, wire progression, 
treatment mechanics and intervals between appointments. The primary outcome of the trial was 
overall treatment duration from appliance insertion to appliance removal in months and the 
secondary outcome was an assessment of outcome after treatment with the use of the Peer 
Assessment Rating (PAR) index (Richmond et al. 1992). Measurements were performed by a 
calibrated external assessor who was not involved in treatment and was blinded to which patient 
belonged to which group. Data were analysed descriptively with mean and standard deviation 
(SD) of each group and differences between groups were checked with Student’s t-test for 
independent samples. They found that considerable differences existed in the treatment duration 
of the experimental group (mean=18.5 months; SD=3.1 months) and the control group 
(mean=24.9 months; SD=4.6 months), which were statistically significant (P<0.001; Table). 
Finally, they found no differences in final PAR score of the experimental group (mean=3.1 points; 
SD=1.4) and the control group (mean=3.6 points; SD=1.7), which was confirmed from the 
statistical analysis (P>0.05). They concluded that Infrabrace is an effective adjunct for reducing 
treatment time with fixed orthodontic appliances. 
 
Based on the above trial report, which of the following statements, if any, are correct: 
(a) The trial robustly assessed the efficacy of Infrabrace. 
(b) The trial robustly assessed the efficiency of Infrabrace. 
(c) Trial outcomes were appropriately measured without bias. 
(d) Differences in the results of the two treatment groups can be attributed to Infrabrace. 
 
Answers 
Statement (c) is true; statements (a), (b), and (d) are false. 
 
(a) The trial robustly assessed the efficacy of Infrabrace. Efficacy in the present example would 
be defined as the extent to which Infrabrace produces a beneficial result under ideal conditions 
(Porta, 2014). The authors measured the occlusal outcome of treatment with PAR scoring and 
found that no significant differences existed between the two groups after treatment (P>0.05). 
Although it cannot be formally concluded that no difference exists in the PAR scores of the two 
groups (since an absence of evidence is not evidence of absence), we can be confident that the 
final PAR scores of the two groups seem very similar. The PAR index can be used to measure 
both the severity of a malocclusion and the outcome of orthodontic treatment (Richmond et al., 
1992). However, no information is given about the initial PAR scores of the two groups, a fact that 
does not let us assess, if equally “difficult” cases were included in each group. A better alternative 
would be to also measure the baseline PAR scores of each case prior to treatment and incorporate 
this in the trial, for example by calculating the absolute or relative PAR change for each patient 
through treatment. We can conclude for the present trial that both the experimental and the control 
protocols can be used to treat to a similar standard (since the final PAR scores of the two groups 
were similar), but we cannot draw any conclusions about the efficacy of Infrabrace (since we do 
not know if the PAR reduction of the two groups were different). 
 
(b) The trial robustly assessed the efficiency of Infrabrace. Efficiency pertains to the effects or end 
results achieved in relation to the effort expended in terms of money, resources, and time (Porta, 
2014). In the present example, if the two groups show similar treatment effects, but the duration 
of treatment is drastically reduced in the Infrabrace group, it then follows that treatment efficiency 
is improved. Following from (a), it is clear that this statement is only partly true, since the authors 
did not robustly assess the efficacy of treatment with Infrabrace. It would be more appropriate to 
say, that if the reduction in PAR score was similar in the two groups, but the time needed to finish 
treatment is reduced with the use of Infrabrace, then treatment efficiency would be improved. 
Another alternative would be to calculate a composite outcome measurement of PAR reduction 
divided by duration, but this might make the trial results and their interpretation more complex. 
Additionally, any improvement in treatment effects or reduction in treatment duration should ideally 
be viewed together with any additional costs of treatment and side effects that might be associated 
with Infrabrace. 
 
(c) Trial outcomes were appropriately measured without bias. The authors used an external 
assessor to measure all trial outcomes, which minimised detection bias. It is known that measuring 
the results of compared interventions can be influenced by a number of factors, including an 
assessor’s personal preferences or present expectations from a trial that has cost plenty of time 
and money to the researchers. As the outcome assessor was blinded, the influence from personal 
preferences or expectations is minimised, while measurement errors are appropriately handled by 
the a priori calibration and post hoc analytic techniques (Bland and Altman, 1986). 
 
(d) Differences in the results of the two treatment groups can be attributed to Infrabrace. This 
statement is false, since the existence of bias cannot be safely ruled out from the present trial. 
True baseline equivalence of experimental and the control groups prior to treatment has not been 
ascertained in the present trial. The outcome of orthodontic treatment might be influenced by 
several known or unknown factors, such as malocclusion severity, patient compliance, the 
genetically-determined biological response of each patient, systematic diseases, smoking, and 
interactions with any medications taken. Ideally, a priori equivalence would be attained through 
random patient allocation in the experimental and control groups, which would ensure that the 
distribution of all known or unknown confounding factors is similar between groups. In this case, 
any differences found between the experimental and the control group could be attributed to the 
supplemental use of Infrabrace. In cases where randomisation is not feasible, statistical methods 
that mimic randomisation like propensity score matching can also be used, although they are more 
complex and not without criticism (Stuart, 2010). Therefore, randomisation is the best approach 
to ensure baseline equivalence in clinical trials of comparative effectiveness. 
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Table. Patient characteristics and outcomes of the given trial example. 
  Experimental Control P value 
Patient characteristics    
 Patients – n 30 30  
 Male/female – n 17/13 14/16  
 Age in years – mean (SD) 13.8 (1.5) 14.1 (2.0)  
Outcomes    
 PAR score after treatment– mean (SD) 3.1 (1.4) 3.6 (1.7) 0.187 
 Treatment duration in years – mean (SD) 18.5 (3.1) 24.9 (4.6) <0.001 
 
SD, standard deviation; PAR, peer assessment rating. 
  
Appendix. Dataset from the given trial example. 
Nr groupcode group txduration par1 par2 sex age 
1 1 experimental 18.57 28 8.00 1 12 
2 1 experimental 15.33 25 3.00 1 12 
3 1 experimental 16.43 26 2.00 0 16 
4 1 experimental 20.07 24 4.00 1 17 
5 0 control 23 18 2.00 0 15 
6 1 experimental 22.1 28 3.00 0 14 
7 1 experimental 18.47 36 2.00 0 13 
8 1 experimental 16 22 3.00 1 13 
9 1 experimental 15.27 24 3.00 1 14 
10 0 control 19.4 33 2.00 1 12 
11 0 control 27.4 24 4.00 1 12 
12 1 experimental 24.3 33 2.00 0 14 
13 1 experimental 16.63 24 2.00 0 13 
14 0 control 28 52 2.00 1 14 
15 1 experimental 17.63 36 2.00 1 14 
16 1 experimental 18.47 29 2.00 1 13 
17 0 control 18.73 25 4.00 1 14 
18 1 experimental 18 21 3.00 0 16 
19 1 experimental 16.3 25 2.00 0 14 
20 1 experimental 15.4 30 3.00 0 16 
21 1 experimental 16.53 23 4.00 1 15 
22 0 control 26.6 53 11.00 0 13 
23 0 control 22.9 29 2.00 0 12 
24 0 control 29.5 53 2.00 0 13 
25 0 control 29.7 23 4.00 1 12 
26 1 experimental 16 30 2.00 0 12 
27 0 control 25.57 24 3.00 1 13 
28 0 control 37.23 43 2.00 1 15 
29 0 control 20.63 33 5.00 0 15 
30 1 experimental 16.33 21 2.00 0 13 
31 0 control 22.73 49 2.00 0 13 
32 1 experimental 16 25 2.00 1 12 
33 0 control 25.7 20 3.00 0 14 
34 0 control 25.23 29 3.00 1 16 
35 1 experimental 16.73 32 6.00 1 15 
36 0 control 20.77 47 9.00 1 19 
37 1 experimental 15 16 2.00 1 12 
38 0 control 21.93 47 2.00 0 19 
39 0 control 31.03 27 5.00 0 15 
40 0 control 24.2 32 2.00 0 14 
41 0 control 22.17 31 3.00 0 12 
42 1 experimental 17 18 3.00 0 13 
43 0 control 25.2 56 7.00 1 14 
44 0 control 26.4 46 4.00 0 15 
45 1 experimental 18 16 4.00 1 15 
46 0 control 26.77 51 19.00 1 12 
47 0 control 36.5 30 4.00 0 12 
48 1 experimental 25.56 49 3.00 1 13 
49 0 control 19 14 4.00 1 14 
50 1 experimental 20.27 36 2.00 1 12 
51 1 experimental 23.9 35 5.00 1 16 
52 1 experimental 19.17 21 2.00 0 13 
53 1 experimental 17.03 25 4.00 0 15 
54 0 control 22.47 31 2.00 1 13 
55 0 control 24.37 39 6.00 0 14 
56 0 control 23 28 2.00 1 12 
57 1 experimental 22.07 39 4.00 1 13 
58 0 control 23.57 41 11.00 1 19 
59 0 control 24.47 27 6.00 0 15 
60 0 control 18.57 19 6.00 0 13 
  
 
